AbbVie Declares Quarterly Dividend
Rhea-AI Summary
AbbVie (NYSE:ABBV) has announced a quarterly cash dividend of $1.64 per share, payable on November 14, 2025, to stockholders of record as of October 15, 2025. The company has demonstrated strong commitment to shareholder returns, increasing its dividend by 310 percent since its inception in 2013.
As a member of the S&P Dividend Aristocrats Index, AbbVie has maintained a track record of consistently increasing its dividend for at least 25 consecutive years, highlighting its financial stability and dedication to shareholder value.
Positive
- Quarterly dividend of $1.64 per share maintained
- 310% dividend increase since 2013
- Member of S&P Dividend Aristocrats Index, showing consistent dividend growth
Negative
- None.
News Market Reaction
On the day this news was published, ABBV declined 0.21%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The cash dividend is payable November 14, 2025, to stockholders of record at the close of business on October 15, 2025.
Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
Media: Gabby Tarbert (224) 244-0111 | Investors: Liz Shea |
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-declares-quarterly-dividend-302547709.html
SOURCE AbbVie
